Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
|
|
Scopus BioPharma Inc. (SCPS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/18/2023 |
8-K
| Quarterly results |
| 08/11/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 12/16/2022 |
8-K
| Quarterly results |
| 12/02/2022 |
8-K
| Quarterly results |
| 10/20/2022 |
8-K
| Quarterly results |
| 10/19/2022 |
8-K
| Quarterly results |
| 10/07/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 09/16/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 09/02/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 07/15/2022 |
8-K
| Quarterly results |
| 05/27/2022 |
8-K
| Quarterly results |
| 05/20/2022 |
8-K
| Quarterly results |
| 05/13/2022 |
8-K
| Quarterly results |
| 05/04/2022 |
8-K
| Quarterly results |
| 04/29/2022 |
8-K
| Quarterly results |
| 04/08/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 03/24/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 03/23/2022 |
8-K
| Investor presentation |
| 03/04/2022 |
8-K
| Quarterly results |
| 02/25/2022 |
8-K
| Changes in Registrant's Certifying Accountant Interactive Data |
| 02/18/2022 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
| 01/20/2022 |
8-K
| Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T... |
| 01/10/2022 |
8-K/A
| Submission of Matters to a Vote of Security Holders, Other Events Interactive Data |
| 12/27/2021 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 11/26/2021 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...|
Docs:
|
"SERIES A ADDITIONAL INVESTMENT OPTION SCOPUS BIOPHARMA, INC. AIO Shares: _______  Issue Date: November 23, 2021 THIS SERIES A ADDITIONAL INVESTMENT OPTION certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to 5:00 p.m. on the five year anniversary of the Authorized Share Increase Date but not thereafter, to subscribe for and purchase from Scopus Biopharma, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this AIO shall be equal to the Exercise Price, as defined in Section 2. Section 1 .      ̷...",
"SERIES B ADDITIONAL INVESTMENT OPTION SCOPUS BIOPHARMA, INC. AIO Shares: _______ Issue Date: November 23, 2021 THIS SERIES B ADDITIONAL INVESTMENT OPTION certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Authorized Share Increase Date and on or prior to 5:00 p.m. on the five year anniversary of the Authorized Share Increase Date but not thereafter, to subscribe for and purchase from Scopus Biopharma, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this AIO shall be equal to the Exercise Price, as defined in Section 2. Section 1 .     ...",
"PLACEMENT AGENT ADDITIONAL INVESTMENT OPTION SCOPUS BIOPHARMA, INC. AIO Shares: _______ Issue Date: November 23, 2021 THIS PLACEMENT AGENT ADDITIONAL INVESTMENT OPTION certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Authorized Share Increase Date and on or prior to 5:00 p.m. on the five year anniversary of the Authorized Share Increase Date but not thereafter, to subscribe for and purchase from Scopus Biopharma, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this AIO shall be equal to the Exercise Price, as defined in Section 2. This AIO is being issued pursuan...",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of November 21, 2021 between Scopus Biopharma, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4 of the Securities Act , and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each ...",
"REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement is made and entered into as of November 21, 2021, between Scopus Biopharma, Inc., a Delaware corporation , and each of the several purchasers signatory hereto . This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser . The Company and each Purchaser hereby agrees as follows: 1. Definitions . Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings: “ Advice ” shall have the meaning set forth in Section 6. “ Effectiveness Date ” means, with respect to the Reg...",
"WARRANT CONTRIBUTION AGREEMENT",
"Scopus BioPharma Announces $9.75 Million Private Placement Priced At-The-Market New York, New York, November 22, 2021 – Scopus BioPharma Inc. , a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced it has entered into securities purchase agreements with certain institutional investors in connection with a private placement priced at-the-market under Nasdaq rules of 3,000,000 shares of common stock, series A additional investment options to purchase up to 1,500,000 shares of common stock, and series B additional investment options to purchase up to 1,500,000 shares of common stock at a purchase price of $3.25 per share and associated AIOs for gross proceeds of $9.75 million, before deduct..." |
|
| 09/30/2021 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 09/13/2021 |
8-K
| Quarterly results |
| 07/09/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/01/2021 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity ... |
| 03/18/2021 |
8-K
| Quarterly results |
| 02/01/2021 |
8-K
| Quarterly results |
| 01/20/2021 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits |
|
|